

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/jtd-23-465">https://dx.doi.org/10.21037/jtd-23-465</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	In particular, data on the change in the proliferation of the tumour cell line caused by the change in the expression level of the lncRNA DINO.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	The statistical analysis plan, study protocol, analysis codes will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique data may be updated over time.
7	To whom will you share the data?	Researchers interested in cisplatin resistance research in lung cancer.
8	For what type of analysis or purpose?	To explore the therapeutic target of lncRNA in lung cancer patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: lz1tonorth@163.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.